Session » Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1588

“Neoplasia in Patients with Systemic LUPUS Erythematosus in Spain: Relesser Registry DATA”

9:00AM-11:00AM: Abstract Number: 1614

“Do You Know What I Mean?” a Tool to Understand What Lupus Patients Comprehend

9:00AM-11:00AM: Abstract Number: 1643

15 Year Comparative Analysis of Cardiovascular Events in Female Subjects with Lupus Versus Controls

9:00AM-11:00AM: Abstract Number: 1647

A Lupus Low Disease Activity State Is Associated with Reduced Flare, Lower Organ Damage Accrual, and Better Quality of Life in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1589

A Multicriteria Decision Analysis for the Development of New Systemic Lupus Erythematosus Classification Criteria

9:00AM-11:00AM: Abstract Number: 1630

Achievement of Lupus Low Disease Activity State (LLDAS) in the Early Phase of Systemic Lupus Erythematosus Prevent Damage Accrual

9:00AM-11:00AM: Abstract Number: 1592

Antimalarial-Induced Cardiomyopathy in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1597

Arthritis and Hydroxychloroquine Are Associated with Decreased Risk of Macrophage Activation Syndrome Among Adults Hospitalized with SLE

9:00AM-11:00AM: Abstract Number: 1615

Assessment of a Cognitive Impairment Measure in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1648

Assessment of Outcome in Lupus Nephritis Patients: A Retrospective Analysis of a Single Center Cohort over 20 Years

9:00AM-11:00AM: Abstract Number: 1622

Associations Among Classification Criteria Items within Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1628

Atrial Fibrillation/Flutter Hospitalizations Among Patients with SLE and Diabetes Compared to the General U.S. Medicaid Population

9:00AM-11:00AM: Abstract Number: 1617

Autoimmune Diseases in Patients with Cutaneous Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1634

Body Mass Index and Disease Activity in Systemic Lupus Erythematosus- a Paradoxical Relationship?

9:00AM-11:00AM: Abstract Number: 1636

Body Mass Index at Disease Onset Is Predictive of Future Organ Damage in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1594

Bone Turnover Markers in Adults with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1635

Cachexia in Systemic Lupus Erythematosus- an Underrecognized Syndrome

9:00AM-11:00AM: Abstract Number: 1606

Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor

9:00AM-11:00AM: Abstract Number: 1646

Cardiovascular disease in Systemic Lupus Erythematosus. The road to hell is paved with good intentions

9:00AM-11:00AM: Abstract Number: 1627

Changes in Heart Rate Variability Reflect Changes in Clinical Status and Patient Reported Outcomes in Systemic Lupus Erythematosus: A Longitudinal Analysis

9:00AM-11:00AM: Abstract Number: 1626

Childhood-Onset Predicts Increased Steroid-Related Damage Among Adults with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1593

Development of Quality Indicator Set of Systemic Lupus Erythematosus in Japan

9:00AM-11:00AM: Abstract Number: 1629

Disease Activity Is an Independent Predictor of Leukopenia in a Large International SLE Cohort

9:00AM-11:00AM: Abstract Number: 1616

Early and Late Onset Biopsy Proven Lupus Nephritis without Other Associated Autoimmune Diseases: Severity and Long-Term Outcome

9:00AM-11:00AM: Abstract Number: 1596

Effect of the Metabolic Syndrome on Organ Damage, Renal Function and Mortality in Patients with Systemic Lupus Erythematosus: A Longitudinal Analysis

9:00AM-11:00AM: Abstract Number: 1608

Entheseal Involvement in Systemic Lupus Erythematosus: An Ultrasound Study

9:00AM-11:00AM: Abstract Number: 1653

Factors Influencing on Health-Related Quality of Life in Female Systemic Lupus Erythematosus Patients with Fibromyalgia

9:00AM-11:00AM: Abstract Number: 1602

Fatigue in Systemic Lupus: The Role of Disease Activity and Its Mediators

9:00AM-11:00AM: Abstract Number: 1599

GRADE-Based Recommendations for the Diagnosis and Monitoring of Systemic Lupus Erythematosus in Canada

9:00AM-11:00AM: Abstract Number: 1620

Habitual Physical Activity, Sedentary Behavior and Cardiovascular Disease Risk Burden in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1638

High Genetic Risk Score Is Associated with Increased Organ Damage in SLE

9:00AM-11:00AM: Abstract Number: 1631

Hospital Readmissions for SLE in the United States: A National Database Study

9:00AM-11:00AM: Abstract Number: 1601

Hydroxychloroquine Non-Adherence Is Associated with Higher Sledai Scores in a Predominantly Hispanic Population

9:00AM-11:00AM: Abstract Number: 1625

Incidence and Outcomes of Venous Thromboembolism in Hospitalized Patients with Systemic Lupus Erythematosus: Results from Nationwide Inpatient Sample Database 2003-2011

9:00AM-11:00AM: Abstract Number: 1611

Increased Body Mass Index May Not be a Risk Factor for the Development of Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1641

Indications for Initial Renal Biopsy in Systemic Lupus Erythematosus: A Systematic Review of the Literature

9:00AM-11:00AM: Abstract Number: 1644

Less Than Seven Hours of Sleep per Night Is Associated with Transitioning to Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1639

Longitudinal Evolution in a Nationwide Cohort Originally Classified As Mixed Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1605

Lupus Low Disease Activity State Protects Against Most Subtypes of Organ Damage in SLE

9:00AM-11:00AM: Abstract Number: 1603

Lupus Low Disease Activity State: Can We Relax the Definition and Still Achieve Low Risk of SLE-Related Damage?

9:00AM-11:00AM: Abstract Number: 1600

Lupus Nephritis Is Associated with Increased Rates of Hospitalization for Adverse Events on a Glucocorticoid Toxicity Index and in-Hospital Mortality Compared with Non-Renal Lupus and Matched Controls: An Analysis of Insurance Claims Data

9:00AM-11:00AM: Abstract Number: 1591

Monophasic Disease Course Pattern in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1587

Mycobacterial Infection in Systemic Lupus Erythematosus: Clinical Significance and Associated Factors. Data from the Registry of Patients with SLE of the Spanish Society of Rheumatology (RELESSER)

9:00AM-11:00AM: Abstract Number: 1613

Natural History of Disease Activity and Damage in Patients with Cutaneous Lupus Erythematosus on Standard of Care Treatments Using Longitudinal Registries from Two Academic Dermatology Centers

9:00AM-11:00AM: Abstract Number: 1654

Predictive Factors According to Type of Infection in Systemic Lupus Erythematosus Patients: Data from a Multi-Ethnic, Multi-National, Latin-American Cohort

9:00AM-11:00AM: Abstract Number: 1595

Prevalence and Predictors of Depression in Patients with Systemic Lupus Erythematosus: Results from the Korean Lupus Network (KORNET) Registry

9:00AM-11:00AM: Abstract Number: 1623

Prevalence of Cognitive Impairment in Systemic Lupus Erythematosus Assessed By a Comprehensive Neuropsychological Battery

9:00AM-11:00AM: Abstract Number: 1621

Prevalence of Cognitive Impairment in Systemic Lupus Erythematosus Assessed By the Automated Neuropsychological Assessment Metrics

9:00AM-11:00AM: Abstract Number: 1612

Primary Respiratory Disease in Patients with Systemic Lupus Erythematosus: Data from the Spanish Rheumatology Society Lupus Registry (RELESSER) Cohort

9:00AM-11:00AM: Abstract Number: 1590

Prolonged Antimalarial Treatment Increases the Risk for Severe Brady-Arrhythmias in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1586

Resistant Hypertension Is Associated with Inflammation, Renal Function, and Increased Mortality in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1618

Risk Factors for Development of Early Infectious and Non-Infectious Complications in Systemic Lupus Erythematosus Patients Undergoing Major Surgery

9:00AM-11:00AM: Abstract Number: 1585

Role of Corticosteroids in Subclinical Atherosclerosis in SLE: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1642

Role of Plaque in Predicting Cardiovascular Events in Women with Lupus over a 20 Year Followup

9:00AM-11:00AM: Abstract Number: 1651

Screening in Patients at High Risk of Hydroxychloroquine Retinal Toxicity

9:00AM-11:00AM: Abstract Number: 1637

Sexual Function in Married Indian Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1598

Shrinking Lung Syndrome in Systemic Lupus Erythematosus Patients: A Diagnosis We Should Suspect More Often

9:00AM-11:00AM: Abstract Number: 1632

SLE Characteristics Associated with Modified Framingham Risk Score in Patients without Clinical Cardiovascular Disease

9:00AM-11:00AM: Abstract Number: 1624

SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K

9:00AM-11:00AM: Abstract Number: 1649

Sleep Disturbances in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1640

SLICC Damage Index Is Associated with Tubulointerstitial Nephritis on Lupus Nephritis Biopsies

9:00AM-11:00AM: Abstract Number: 1609

Telomere Length and Coronary Artery Atherosclerosis in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1610

The Impact of Alcohol Use on Cardiovascular Events and Overall Mortality in Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1619

The Impact of Disease Characteristics on Habitual Physical Activity and Sedentary Behavior Among Patients with Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1650

The Montreal Cognitive Assessment Questionnaire (MoCA): A Promising Screening Tool for Cognitive Dysfunction in SLE

9:00AM-11:00AM: Abstract Number: 1645

Tobacco Exposure and Relationship with Severe Damage in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1652

Trajectories of Quality of Life in an Iception Cohort of Lupus Patients and Their Determinants

9:00AM-11:00AM: Abstract Number: 1607

Tumor-Related Autoantibodies and Cancers in SLE: A Case-Control Study from a Single Centre

9:00AM-11:00AM: Abstract Number: 1633

Use of Emergency Department (ED) and Resulting Hospitalization By Patients with Systemic Lupus Erythematosus (SLE) in a Predominantly Afro-Caribbean Inner-City Cohort

9:00AM-11:00AM: Abstract Number: 1604

Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].